Clinical trial
Phase I Study of Lenalidomide to Augment Anti-Tumor Immunity Following Allogeneic Transplantation
NCT01750762 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of Lenalidomide to Augment Anti-Tumor Immunity Following Allogeneic Transplantation
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- December 31, 2012
- Completion date
- March 31, 2014
- Enrollment
- 1 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.